The global Peptide API CDMO Services market size is projected to grow from US$ 2291 million in 2024 to US$ 5489 million in 2030; it is expected to grow at a CAGR of 15.7% from 2024 to 2030.
ReportPrime' newest research report, the “Peptide API CDMO Services Industry Forecast” looks at past sales and reviews total world Peptide API CDMO Services sales in 2022, providing a comprehensive analysis by region and market sector of projected Peptide API CDMO Services sales for 2023 through 2029.
This Insight Report provides a comprehensive analysis of the global Peptide API CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.
Segmentation by Type:
- GMP Services
- Non-GMP Services
Segmentation by Application:
- Commercial
- Scientific Research
- Other
Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
Company’s Coverage:
- Bachem
- PolyPeptide
- CordenPharma
- AmbioPharm
- USV Peptides
- Thermo Fisher
- Bio Basic
- JPT
- Genscript
- Chinese Peptide Company
- ScinoPharm
- ChengDu ShengNuo Biotec
- CBL
- Piramal Pharma
- CPC Scientific
Key Questions Addressed in this Report:
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market